Table 1 Baseline clinicopathologic characteristics.
Character | Number | Percent |
|---|---|---|
Number of patients | 30 | 100.0% |
Median age, years (range) | 62.0 [31.0, 75.0] | |
Gender | ||
Male | 21 | 70.0% |
Female | 9 | 30.0% |
ECOG performance status | ||
0 | 23 | 76.7% |
1 | 7 | 23.3% |
Smoking history | ||
Yes | 17 | 56.7% |
No | 13 | 43.3% |
Primary tumor site | ||
Whole stomach | 3 | 10.0% |
Gastroesophageal junction/Cardia | 7 | 23.3% |
Fundus/body | 9 | 30.0% |
Antrum | 11 | 36.7% |
Histological grade | ||
Moderately differentiated | 8 | 26.7% |
Poorly differentiated | 15 | 50.0% |
Unknown | 7 | 23.3% |
TNM stage | ||
Stage III | 6 | 20.0% |
Stage IV | 24 | 80.0% |
Metastasis | ||
M0 | 8 | 26.7% |
M1 | 22 | 73.3% |
Metastatic sites | ||
Liver | 11 | 36.7% |
Peritoneum | 10 | 33.3% |
Lymph nodes | 9 | 30.0% |
Bone | 1 | 3.3% |
Number of metastatic sites | ||
0–2 | 28 | 93.3% |
≥ 3 | 2 | 6.7% |
Pathological pattern | ||
Adenocarcinoma | 25 | 83.3% |
Signet-ring cell carcinoma | 5 | 16.7% |
HER-2 status | ||
Positive | 7 | 23.3% |
Negative | 23 | 76.7% |
EBV Status | ||
Negative | 27 | 90.0% |
Positive | 1 | 3.3% |
Unknown | 2 | 6.7% |
MSI status | ||
MSS | 30 | 100.0% |
TMB | ||
Median TMB (range) | 8.10 [2.79, 30.7] | |
TMB-H | 11 | 36.7% |
TMB-L | 19 | 63.3% |
Chemotherapy regimens | ||
SOX | 21 | 70.0% |
DX | 4 | 13.3% |
XELOX | 3 | 10.0% |
FOLFOX | 2 | 6.7% |
PD-1 monoclonal antibody | ||
Sintilimab | 26 | 86.7% |
Nivolumab | 4 | 13.3% |
